Acute leukemias : pharmacokinetics and management of relapsed and refractory disease
Author(s)
Bibliographic Information
Acute leukemias : pharmacokinetics and management of relapsed and refractory disease
（Haematology and blood transfusion = Hämatologie und Bluttransfusion, 34）
Springer-Verlag, c1992
Available at / 4 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Following the major breakthroughs in the and frequent and thorough exchange of treatment of acute leukemias in the seven- information. Hence, it was felt that a spe- ties by the introduction of intensive combi- cial series of symposia should be devoted to nation regimens, therapeutic progress has "Pharmacokinetics and Management of slowed down and the impression of stagna- Relapsed and Refractory Disease" comple- menting the established meetings on "Prog- tion may even have occured. In contrast, the knowledge about the biology of leu- nostic Factors and Treatment Strategies" kemias is rapidly expanding and allows new which will proceed in parallel. It was the insights into the pathophysiology of the aim of the international symposium disease. Further improvements also come "ACUTE LEUKEMIAS - Pharmacokine- from a better understanding of the pharma- tics and Management of Relapsed and cokinetics and pharmacodynamics of cyto- Refractory Disease" to provide an update static drugs and their mechanisms of action. of the present knowledge in this area and to Hence, novel treatment modalities can be stimulate further developments.
As a sign developed on a more solid basis and ration- for the closing distance between countries al. These achievements need to be comple- and the development of effective world- mented by effective eradiation wide cooperation this symposium emerged of residual disease or its permanent control and new from the joint efforts of the German AML approaches have been derived from recent Cooperative Group and the M. D.
Table of Contents
Drug Resistance in Leukemia.- Multidrug Resistance and Its Circumvention in Acute Leukemia.- The Role of DNA Topoisomerase II in Multidrug Resistance in Human Leukemia.- Development of Sensitive Assays to Detect Antifolate Resistance in Leukemia Blasts.- Sequential Analysis of P-Glycoprotein Expression in Childhood Acute Lymphoblastic Leukemia.- Expression of the MDR1 Gene and Treatment Outcome in Acute Nonlymphocytic Leukemia.- Multidrug Resistance Proteins and their Functional Modulation in Human Leukemias as Analyzed by Flow Cytometry.- Reversal of Multidrug Resistance with a New Calcium/Calmodulin Antagonist.- Characterization of Human Leukemic HL-60 Sublines as a Model for Primary and Secondary Resistance Against Cytostatics.- Conserved Cytotoxic Activity of Aclacinomycin A in Multifactorial Multidrug Resistance.- Cytostatic Drug Resistance and Differentiation in Friend Erythroleukemia Cells.- On the Role of Aldehyde Dehydrogenase in a Cyclophosphamide-Resistant Variant of Brown Norway Rat Acute Myelocytic Leukemia.- SAENTA-Fluoresceins: New Flow Cytometry Reagents for Assessing Transport of Nucleoside Drugs in Acute Leukemia.- Hematopoietic Growth Factors in Leukemia Therapy.- Human Stem Cell Factor: Biological Effects and Receptor Expression on Myeloid Leukemia Cells.- Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor Following Chemotherapy in Patients with High-Risk AML.- Use of Granulocyte-Macrophage Colony Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML.- G-CSF after Intensive Induction Chemotherapy in Refractory Acute Leukemia and Bone Marrow Transplantation in Myeloid Leukemia.- Cytokinetic Resistance in Acute Leukemia: Recombinant Human Granulocyte Colony-Stimulating Factor, Granulocyte Macrophage Colony-Stimulating Factor Interleukin-3 and Stem Cell Factor Effects in Vitro and Clinical Trials with Granulocyte Macrophage Colony-Stimulating Factor.- Simultaneous Administration of Granulocyte-Macrophage Colony-Stimulating Factor and Cytosine Arabinoside for the Treatment of High-Risk Myeloid Leukemia.- Modulation of Cytotoxicity and Differentiation-Inducing Potential of Cytosine Arabinoside in Myeloid Leukemia Cells by Hematopoietic Cytokines.- The Effect of Growth Factors on the Sensitivity of CFU-GM and CFU-Blasts to Cytosine Arabinoside.- Proliferation-Inducing Effects of Recombinant Human Interleukin-7 and Interleukin-3 in B-Lineage Acute Lymphoblastic Leukemia.- Interleukin-1 Production by Mononuclear Cells and Natural Killer Cell Activity in Children with Acute Lymphoblastic Leukemia.- Lymphokine Combination Vectors: A New Tool for Tumor Vaccination in Leukemias/Lymphomas.- Regulation of Erythropoietin Production in Patients with Myelodysplastic Syndromes.- Characterization of Complete Remission - Molecular Biologic and Cytogenetic Approaches.- Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia Patients by Polymerase Chain Reactions.- Detection of Minimal Residual Disease in B-Lineage Leukemia by Immunoglobulin Gene Fingerprinting.- Probing the Pathophysiology of Leukemic Response by Premature Chromosome Condensation.- Combination of In Situ Hybridization Cytogenetics and Immunologic Cell Identification in Diagnosing Minimal Residual Disease.- Detection of Residual Leukemic Cells in AML.- Detection of Residual Leukemic Cells in the Majority of AML Patients After the Administration of TAD9.- Flow Cytometric Characterization of Therapy-Resistant Leukemic Subpopulation in Relapse.- Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneitiy and Resistance in Acute Leukemia.- Myelomonocyte Differentiation Antigens in the Diagnosis of Acute Nonlymphocytic Leukemia: the Relevance of CDw65 Antigen as a Screening Marker and the Prognostic Significance of CD15 Expression.- Surveillance of Acute Leukemia by Multiparameter Flow Cytometry.- Bone Marrow Blast Count at Day 28 as the Single Most Important Prognostic Factor in Childhood Acute Lymphoblastic Leukemia.- GM-CSF, CD14, and c-fms Genes in 12 Patients with 5q Abnormalities.- Characterization of the Predominant T-Cell Receptor Delta (TCRS) Rearrangements in Non T, Non-B ALL.- Diagnosis of Both c-ALL and Sarcoidosis in the Same Patient.- Pharmacokinetics - Preclinical Investigations and Therapeutic Implications.- Pharmacologically Guided Leukemia Therapy.- Biochemical Basis for Combination Chemotherapy.- Interaction of Cytosine Arabinoside Accumulation and Cytosine Arabinoside Triphosphate Formation with Various Cytotoxic Drugs.- Dose-Dependent Cellular and Systemic Pharmacokinetics of Cytosine Arabinoside.- Enhanced Accumulation of dFdC Triphosphate in Tumor Cells with Short Retention of ARA-C-Triphosphate.- Intracellular Pharmacokinetics of Cytosine Arabinoside in Leukemic and Normal Blood Cells.- Therapy of Relapsed Acute Myeloid Leukemia Using Targeted Plasma Concentrations of Cytosine Arabinoside and Etoposide.- Pharmakokinetics of High-Dose Etoposide Given in Diluted or Undiluted Form.- Clinical Implications of Idarubicin Pharmacology.- Mitoxantrone: Pharmacokinetic and Pharmacodynamic Studies in Patients with Leukemia.- Pharmacological Sanctuaries in the Treatment of Acute Leukemia in the Rat.- In Vitro Drug Resistance in Childhood Acute Lymphoblastic Leukemia in Relation to Age and Immunophenotype.- Drug Resistance in Children with Relapsed Acute Lymphoblastic Leukemia.- Sensitivity of Childhood Acute Lymphoblastic Leukemia Cells to Prednisolone and Dexamethasone Assessed by the MTT Assay.- Correlation of In Vitro Drug Resistance Assessed by the MTT Assay with Long-Term Clinical Outcome in Childhood Acute Lymphoblastic Leukemia.- Prognostic Significance of Exposure to Intermediate-Dose Methotrexate in Children with Standard Risk ALL: The COALL 82/85 Experience.- Protein Binding of Teniposide In Vitro and in Children with Acute Lymphoblastic Leukemia.- Effect of Carboxymethylglucan-ara-C on Experimental Leukemia.- Plasma Pharmacology of Fludarabine and Cellular Bioavailability of Fludarabine Triphosphate.- Pharmacology of High-Dose 1,2,4 Triglycidylurazol in Preparative Regimes for Bone Marrow Transplantation: Preclinical Evaluation and First Clinical Results.- 2,2'-Difluorodeoxycytidine: A New Antimetabolite with Inhibitory Activity Against Ribonucleotide Reduction and dCMP Deaminase.- Screening of 19 Monoclonal Antibodies for their Potential as Ricin A-Chain Immunotoxins Against Myeloid Leukemia Cell Lines.- Clinical Trials in Relapsed and Refractory Acute Myeloid Leukemia.- Patterns of Failure in Salvage Therapy for Acute Myelogenous Leukemia.- Cancer and Leukemia Group B Studies in Relapsed AML.- Clinical Trials in Adults with Relapsed and Refractory Acute Myelogenous Leukemia: The ECOG and the University of Rochester Experience.- Intermediate-Dose Cytarabine in the Treatment of Relapsed or Refractory Leukemias.- Mitoxantrone, Etoposide, and Intermediate-Dose Cytosine Arabinoside (MEC): An Effective Regimen for Refractory Acute Myeloid Leukemia.- Intermediate-Dose Arabinoside and Amsacrine: An Effective Regimen in Relapsed and Refractory Acute Leukemia.- High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison.- Treatment of Refractory and Relapsed Childhood Acute Myelogenous Leukemia with High-Dose Cytosine Arabinoside and Mitoxantrone (HAM): Results of the AML Relapse Study BFM-85.- Sequential Standard-Dose Cytosine Arabinoside/Mitoxantrone Therapy (SAM) in Adults with Acute Myeloid Leukemia.- Acute Myeloid Leukemia: An Update of Treatment Results with High-Dose Ara-C Consolidation Therapy.- Continuous Infusion of Mitoxantrone Combined with High-Dose Cytarabine (c-HAM) in Acute Myeloblastic Leukemia.- Treatment of Refractory and Relapsed Acute Leukemias with Cytosine Arabinoside and Mitoxantrone.- Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results.- Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in "Response-Adapted" Sequence.- Use of AMSA Combination Chemotherapy in Patients with Acute Myelogenous Leukemia Unsuitable for Anthracycline or Mitoxantrone Treatment.- Treatment of High-Risk Relapsing or Refractory AML with M-AMSA and ID-ARAC.- Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: A Phase II Study of the Arbeitsgemeinschaft Internistische Onkologie.- Therapeutic Choices Influencing Duration of Complete Remission in Acute Myelogenous Leukemia.- Intensive Antileukemic Treatment for Advanced Primary Myelodysplastic Syndromes: Analysis of 30 Patients.- Treatment of Relapsed or Refractory Adult Acute Lymphocytic Leukemia.- Mitoxantrone and Continuous Infusion of Cytosine Arabinoside in the Treatment of Relapsed and Refractory Acute Leukemia.- Oral Idarubicin in Pretreated Pediatric Acute Leukemia.- Involvement of the CNS in Childhood AML: Experiences of the AML-BFM-Studies-78, -83, and 87.- Modified REZ BFM 87 Protocol in Relapsed Childhood ALL: A Preliminary Report.- Platelet Transfusion in Patients with Bone Marrow Aplasia.- Renal Failure in Acute Leukemia: Incidence, Cause and Clinical Outcome.- Post Remission Therapy.- Marrow Transplantation in Patients with Acute Myeloid Leukemia in First Remission, First Relapse or Second Remission.- Possible Effect of Autologous Blood Stem Cell Transplantation on the Outcome of Acute Myeloid Leukemia in First Relapse.- Therapy of Acute-Phase Chronic Myelogenous Leukemia with Intensive Chemotherapy, Blood Cell Autotransplantation and Cyclosporine A.- Allogeneic Bone Marrow Transplantation in Patients with Acute Leukemia with More Advanced Disease.- Engraftment-Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation.- Impact of Total Body Irradiation and Marrow Transplantation in Early and Advanced Leukemia.- High-Dose ARA-C, Cyclophosphamide and Etoposide with Noncryopreserved Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in Remission: A Pilot Study.- Autologous Bone Marrow Transplantation in Patients with Acute Lymphoblastic Leukemia in Second or Subsequent Complete Remission.- Two Murine Leukemia Models for the Investigation of New Treatment Strategies in Bone Marrow Transplantation.- Immunomagnetic Removal of Malignant Cells from Human Bone Marrow Prior to Autologous Bone Marrow Transplantation.- High-Dose VP-16 (HD VP-16) and Fractionated Total Body Irradiation (F TBI) Followed by Autologous Bone Marrow Transplantation (ABMT) in Children with Relapsed or High-Risk Acute Lymphoblastic Leukemia (ALL).- Understanding the Mechanisms of Cure in Acute Myeloblastic Leukaemia: Towards a Modern Immunotherapy.- Interleukin 2 Treatment in the Management of Acute Leukemia Patients.- Assessment of Lymphokine-Activated Killer Activity Against Myeloid Leukemic Blasts and the Myeloid Cell Line K562 by Flow Cytometry.- Effect of Cyclosporine on the Frequency of LAK Precursor Cells in Vivo and In Vitro.- Adoptive Immunotherapy in Human and Canine Chimeras.- Interleukin-2 in the Treatment of Acute Myelocytic Leukemia: In Vitro Data and Presentation of a Clinical Concept.- Idarubicin: New Aspects in the Treatment of Acute Leukemias.- State of the Art and Future Prospects of the Treatment of Acute Myeloid Leukemia.- Idarubicin Pharmacokinetics.- Toxicity Profile of Idarubicin: Experiences with Oral and Intravenous Idarubicin in the Treatment of Leukemia.- Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia.- Novantrone: Current Status and Future Trends in the Treatment of Leukemias and Lymphomas.- New Aspects in the Pharmacokinetics and Metabolism of Mitoxantrone.- Mitoxantrone in the Treatment of Acute Leukemias.- High-Dose Cytosine Arabinoside and Mitoxantrone (HAM) in the Treatment of Acute Leukemias: Results of Salvage and First Line Treatment.- Mitoxantrone, Cytosine Arabinoside and VP-16 (MAV) for De Novo Acute Myeloid Leukemia Leukemia: A Pilot Study.- Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin's Lymphoma.- Treatment of Low-Malignant Non-Hodgkin's Lymphoma by Cytoreductive Chemotherapy with Prednimustine/Mitoxantrone (PmM) Followed by Interferon-? 2b Maintenance.
by "Nielsen BookData"